title: Clinical and biochemical effects of calcium-hopantenate on neuroleptics-induced tardive dyskinesia.
abstract: Calcium-hopantenate (HOPA), a derivative of GABA, was administered to 9 psychiatric patients with neuroleptics-induced tardive dyskinesia. In a clinical study, involuntary movements have improved significantly after a 4-8-week medication. Although there was no correlation between the cerebrospinal fluid (CSF) levels of HOPA, GABA, HVA or clinical response, the CSF HOPA levels significantly correlated with changes in the CSF GABA levels. These results suggest that HOPA alleviates the symptoms of tardive dyskinesia being mediated by the central GABAergic mechanisms.
authors.forename: K
authors.initials: K
authors.lastname: Kashihara
authors.forename: T
authors.initials: T
authors.lastname: Ebara
authors.forename: M
authors.initials: M
authors.lastname: Yamamoto
authors.forename: T
authors.initials: T
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Harada
authors.forename: S
authors.initials: S
authors.lastname: Otsuki
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D004409:Dyskinesia, Drug-Induced / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010205:Pantothenic Acid / Q000031:analogs & derivatives* / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000134:cerebrospinal fluid / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; C016030:pantogab; D010205:Pantothenic Acid; D005680:gamma-Aminobutyric Acid